<DOC>
	<DOCNO>NCT00102440</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy febuxostat , daily ( QD ) , versus allopurinol subject gout .</brief_summary>
	<brief_title>Febuxostat Versus Allopurinol Control Trial Subjects With Gout</brief_title>
	<detailed_description>This randomize , control , double-blind study 52 week duration . Subjects receive prior urate-lowering therapy underwent 2-week washout period prior randomization . Subjects randomize one three treatment group : febuxostat 80 milligram ( mg ) , febuxostat 120 mg , allopurinol 300 mg. Naproxen ( 250 mg twice daily ) colchicine ( 0.6 mg daily ) provide prophylaxis acute gout flare washout period first 8 week double-blind treatment .</detailed_description>
	<mesh_term>Gout</mesh_term>
	<mesh_term>Febuxostat</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<criteria>Meeting preliminary criterion American Rheumatism Association classification acute arthritis primary gout . Serum uric acid ≥ 8.0 milligram per deciliter ( mg/dL ) Baseline Serum creatinine &gt; 1.5 mg/dL Calculated creatinine clearance &lt; 50 milliliter per minute ( mL/min ) Pregnancy lactation ; Concurrent therapy urate lower agent , azathioprine , 6mercaptopurine , thiazide diuretic , medication contain aspirin ( &gt; 325 mg ) salicylates ; Body Mass Index ( BMI ) &gt; 50 kilogram per meter² ( kg/m² ) ; A history xanthinuria , active liver disease , hepatic dysfunction ; A history alcohol abuse intake 14 alcoholcontaining drinks/week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>uric Acid</keyword>
	<keyword>xanthine oxidase</keyword>
	<keyword>tophus</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>